Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in Indonesia-Reference-Cited by-同舟云学术

Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in Indonesia

Published:2023-05 Issue:5 Volume:23 Page:545-555
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Fadlyana Eddy,Setiabudi Djatnika,Kartasasmita C B,Putri Nina Dwi,Rezeki Hadinegoro Sri,Mulholland Kim,Sofiatin Yulia,Suryadinata Hendarsyah,Hartantri Yovita,Sukandar Hadyana,Indrati Agnes Rengga,Murad Chrysanti,Setiawaty Vivi,Pangesti Krisna Nur Andriana,Multihartina Pretty,Khrisna Citra Vravita,Ayuninda Masayu Riela,Wicaksana Pratama,Zhafira Aqila Sakina,Sinto Robert,Rusmil Kusnandi,Sundoro Julitasari,Watts Emma,Nguyen Cattram

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference11 articles.

1. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: an interim analysis in Indonesia;Fadlyana;Vaccine,2021

2. Fractionation of COVID-19 vaccine doses could extend limited supplies and reduce mortality;Cowling;Nat Med,2021

3. Reflection paper on the regulatory requirements for vaccines intended to provide protection against variant strain(s) of SARS-CoV-2;Eur Med Agency Comm Hum Med Prod Reflect,2021

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Improvement of Adaptive Immune Responses towards COVID-19 Following Diphtheria–Tetanus–Pertussis and SARS-CoV-2 Vaccinations in Indonesian Children: Exploring the Roles of Heterologous Immunity;Vaccines;2024-09-09

2. Equal Maintenance of Anti-SARS-CoV-2 Antibody Levels Induced by Heterologous and Homologous Regimens of the BNT162b2, ChAdOx1, CoronaVac and Ad26.COV2.S Vaccines: A Longitudinal Study Up to the 4th Dose of Booster;Vaccines;2024-07-18

3. Long Term Follow Up of Antibody Titres Against SARS-CoV-2 6 Months After Primary Protein Subunit COVID-19 Vaccination (ZF2001) in Indonesian Adults and Older Adults;Open Access Journal of Clinical Trials;2024-07

4. Heterologous versus homologous COVID-19 booster vaccinations for adults: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials;BMC Medicine;2024-06-24

5. Immunogenicity and Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (IndoVac®) as a Booster Dose against COVID-19 in Indonesian Adults;Vaccines;2024-05-14